While Geron Corporation (NASDAQ:GERN) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 29% in the last quarter.

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Geron (GERN), the biopharmaceutical company behind the approved telomerase inhibitor for specific lower-risk myelodysplastic syndromes, has experienced significant success with its product RYTELO.

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The ...